<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104633</url>
  </required_header>
  <id_info>
    <org_study_id>DEGENCA</org_study_id>
    <nct_id>NCT04104633</nct_id>
  </id_info>
  <brief_title>Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the &quot;Massive Parallel Sequencing&quot; on Circulating Tumor DNA</brief_title>
  <official_title>Feasibility Study of a Molecular Karyotype Using a Very High-throughput Sequencing Approach, the &quot;Massive Parallel Sequencing&quot; on Circulating Tumor DNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Henri Duffaut - Avignon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Henri Duffaut - Avignon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There are several types of circulating DNA: DNA from patient's existing cells, foetal DNA in
      the case of pregnant woman, and tumoral DNA in the case of patients with cancer. These
      circulating tumoral DNA (ctDNA) can be obtained from a blood test called liquid biopsy and be
      detected by the latest generation of very high throughput sequencers with the Massive
      Parallel Sequencing technique (MPS).

      This study focus on using this technique on breast and colorectal cancers in which no
      analysis of CNV (tumor origin marker) with this technique has been performed yet. It is a
      prospective, pilot, monocentric, feasibility study on genomic profile. The study aim is to
      show the possibility to realize in a reproductive way a molecular karyotype on ctDNA with the
      MPS approach from a liquid biopsy taken from patients with cancer and to compare this profile
      with the one obtained by CGH array (Comparative Genomic Hybridization) from primitive tumor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of molecular karyotype performed from liquid biopsy: copies number variations (CNV)</measure>
    <time_frame>Up to surgery</time_frame>
    <description>Feasibility of molecular karyotype showing acquired copies number variations (CNV) on whole genome performed from ctDNA isolated from blood sample in patients with breast or colorectal cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of patient's tumor genomic profile with blood sample</measure>
    <time_frame>Up to surgery</time_frame>
    <description>Identification of patient's tumor genomic profile by comparison between genomic profile of primitive tumor obtained by CGH array and genomic profile of ctDNA obtained by Massive Parallel Sequencing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with breast or colorectal cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>10 patients with invasive breast carcinoma, not otherwise specified (NOS) (Stade I to III) and 10 patients with invasive colorectal adenocarcinoma (Stade I to III)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>30 ml of blood collection</description>
    <arm_group_label>Patients with breast or colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Signed consent

          -  Women with invasive breast carcinoma, NOS, with a radiologically measurable tumor of
             more than 10 mm (stade I to III)

          -  Patients with invasive colorectal adenocarcinoma with a radiologically measurable
             tumor of more than 10 mm (stade I to III)

          -  Patients who primary surgery is planned

        Exclusion Criteria:

          -  Neoadjuvant chemotherapy or neoadjuvant radiotherapy

          -  Other cancer

          -  BMI &gt; 30

          -  Pregnant woman

          -  Patients under protective administration or deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume GRANIER, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Henri Duffaut</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume GRANIER, MD</last_name>
    <phone>+33432753270</phone>
    <email>ggranier@ch-avignon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume GRANIER, MD</last_name>
      <phone>+33432753270</phone>
      <email>ggranier@ch-avignon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ctDNA</keyword>
  <keyword>Molecular karyotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

